Skip to main content
main-content

Genitourinary cancers

News and opinion

19-08-2019 | FGFR inhibitors | Highlight | News

Early data show promise for the FGFR inhibitor rogaratinib

The FGFR inhibitor rogaratinib is well tolerated and clinically active in patients with various tumor types selected for treatment on the basis of FGFR mRNA overexpression, phase I study data show.

16-08-2019 | EMA | News

EMA adopts new indications for pembrolizumab, atezolizumab

Click through to find out which additional patient groups can now receive these drugs

15-08-2019 | Urothelial cancer | News

Gemcitabine–eribulin shows promise for cisplatin-ineligible urothelial carcinoma

Phase II study data suggest favorable treatment response and survival with first-line gemcitabine–eribulin in cisplatin-ineligible patients with metastatic urothelial carcinoma.

13-08-2019 | Prostate cancer | Highlight | News

Meta-analysis supports MRI plus targeted biopsy for prostate cancer diagnosis

Prebiopsy multiparametric magnetic resonance imaging plus targeted biopsy is associated with increased detection of clinically significant prostate cancer versus ultrasonography-guided systematic biopsy alone, study data show.

09-08-2019 | Prostate cancer | News

‘Superior’ detection of biochemical recurrence with PSMA PET–CT

68Ga-prostate-specific membrane antigen-11 should be the “tracer of choice” for PET–CT to detect the postoperative biochemical recurrence of prostate cancer, say researchers who conducted a comparative imaging trial.

08-08-2019 | Urothelial cancer | News

Balance needed for short- vs long-term immunotherapy risks, benefits in mUC

Patients with cisplatin-ineligible metastatic urothelial carcinoma have decreased short-term overall survival when receiving immunotherapy versus carboplatin-based chemotherapy in the first line, but increased long-term survival, study findings indicate.

05-08-2019 | Prostate cancer | Highlight | News

HIV infection associated with worse prostate cancer outcomes

Older individuals with HIV and prostate cancer have worse outcomes than corresponding cancer patients without HIV, according to a large database study from the USA.

02-08-2019 | FDA | News

Darolutamide added to armamentarium for nonmetastatic CRPC

Read more about this US FDA approval here

31-07-2019 | Nivolumab | News

Durable survival with nivolumab in patients with advanced RCC, NSCLC

Five-year data from the phase I CA209-003 trial indicate that the PD-1 inhibitor nivolumab is associated with long-term survival benefits among heavily pretreated patients with advanced renal cell carcinoma or non-small-cell lung cancer.

30-07-2019 | Prostate cancer | News

Decision aids unlikely to influence men considering prostate cancer screening

Current decision aids probably have no influence on whether physicians and patients discuss prostate cancer screening or decide to undergo screening, according to a systematic review and meta-analysis.

24-07-2019 | Erdafitinib | Highlight | News

Erdafitinib shows promising efficacy in advanced urothelial carcinoma

The pan-FGFR inhibitor erdafitinib could be a treatment option for previously treated patients with locally advanced or metastatic urothelial carcinoma harboring FGFR aberrations, suggest phase II trial results.

23-07-2019 | Bladder cancer | News

Nomogram-predicted recurrence risk may aid adjuvant chemotherapy stratification in MIBC

Muscle-invasive bladder cancer patients with a nomogram-derived 1-year recurrence probability of at least 40% are likely to benefit from adjuvant chemotherapy, suggests a retrospective study.

19-07-2019 | Bladder cancer | News

NCCN releases guidance for bladder cancer patients

The National Comprehensive Cancer Network has issued patient-oriented guidelines to help individuals with bladder cancer better understand and manage their condition.

17-07-2019 | Androgen deprivation therapy | Highlight | News

ADT use associated with Alzheimer’s disease, dementia

Older prostate cancer patients who use androgen deprivation therapy may be at increased risk for developing Alzheimer’s disease or dementia, findings indicate.

Click through for comments from study author Ravishankar Jayadevappa and independent expert David Robinson.

16-07-2019 | Ramucirumab | News

Phase I data support dual VEGFR2, PD-1 inhibition

Phase I study data suggest that ramucirumab plus pembrolizumab is a feasible treatment option for patients with previously treated advanced non-small-cell lung cancer, urothelial carcinoma, and gastric or gastroesophageal junction adenocarcinoma.

11-07-2019 | Prostate cancer | News

Conservative management increasing in younger prostate cancer patients

Rates of active surveillance or watchful waiting among younger men with low‐risk prostate cancer have quadrupled in recent years but remain below those for older men, despite no apparent increased mortality risk, research shows.

10-07-2019 | Castration-resistant prostate cancer | News

Glucocorticoid regimens explored in mCRPC

Combining abiraterone acetate with a relatively high dose of prednisone or dexamethasone may reduce mineralocorticoid excess toxic effects, but can result in increased metabolic toxicity, study data show.

04-07-2019 | Prostate cancer | News

EBRT has smallest impact on sexual function after prostate cancer diagnosis

Among the potential active treatment options for prostate cancer, external‐beam radiotherapy alone results in the best preservation of sexual function up to 2 years after treatment, population-based study data show.

01-07-2019 | Renal cell carcinoma | News

Targeted therapy can benefit complex patients with advanced RCC

Targeted therapy improves survival over nontargeted therapy among patients with metastatic renal cell carcinoma, including those who are older and have disabilities, shows an analysis of real-world data.

28-06-2019 | Immunotherapy | Highlight | News

Checkpoint inhibitor rechallenge feasible after irAE-related discontinuation

Two studies point to the feasibility of resuming immune checkpoint inhibitors in patients who discontinue treatment due to immune-related adverse events.

Image Credits